Funder: U.S. Food and Drug Administration (FDA)

As part of FDA's Advancing Regulatory Science Initiative, the Office of the Chief Scientist supports innovation aimed at development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.

This funding opportunity will provide support, depending on availability of FDA funding, for the existing Center of Excellence in Regulatory Science and Innovation (CERSI) at University of California, San Francisco-Stanford University. This CERSI will serve to advance the Agency's regulatory science goals predominantly through cutting-edge collaborative research with FDA; they may also provide training in regulatory science.

Topics: Computational Analysis, Diagnostics, Antibody Detection, Diagnostics Development, Diagnostic Efficacy, Diagnostic Reliability, Diagnostic Scalability, Viral Detection, Product Development and Commercialization, Prognostics, Treatments, Antibody-based Treatment, Convalescent Serum, Drug Development, Drug Repurposing, Drug Targets, Anti-viral Targets, Immunological Response Targets, Treatment Efficacy, Treatment Reliability, Treatment Scalability, Vaccine Development, Vaccine Efficacy, Vaccine Reliability, Vaccine Scalability, Vaccines